Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hepatitis b: experimental combo aims to clear the virus

NCT ID NCT04856085

Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on antiviral therapy took part. The goal was to see if these combinations could achieve undetectable virus levels and possibly allow patients to stop lifelong medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

244 people

The number who actually took part.

Started

Jul 2021

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female ages 18 - \<66 years * Chronic HBV infection for \>/= 6 months * On NRTI therapy for \>/= 2 months at the time of screening Exclusion Criteria: * Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation * Significant fibrosis or cirrhosis * History or evidence of drug or alcohol abuse * History of chronic liver disease from any cause other than chronic HBV infection * History of hepatic decompensation * History of anaphylaxis * History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434 * History of immune complex disease * History of known contraindication to any interferon product

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis B, chronic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis B, chronic

Contacts and locations

Locations

  • Investigative Site

    San Francisco, California, 94143, United States

  • Investigative Site

    Miami, Florida, 33136, United States

  • Investigative Site

    Orlando, Florida, 32803, United States

  • Investigative Site

    Baltimore, Maryland, 21218, United States

  • Investigative Site

    Hillsborough, New Jersey, 08844, United States

  • Investigative Site

    Toronto, 2C4, Canada

  • Investigative Site

    Toronto, 3M1, Canada

  • Investigative Site

    Vancouver, 2C7, Canada

  • Investigative Site

    Frankfurt, 60590, Germany

  • Investigative Site

    Hanover, 30625, Germany

  • Investigative Site

    Mannheim, 68167, Germany

  • Investigative Site

    Hong Kong, Shatin, Hong Kong

  • Investigative Site

    Hong Kong, Tai Po District, Hong Kong

  • Investigative Site

    Hong Kong, Hong Kong

  • Investigative Site

    Kuala Lumpur, 59100, Malaysia

  • Investigative Site

    Chisinau, MD 2025, Moldova

  • Investigative Site

    Auckland, 1010, New Zealand

  • Investigative Site

    Auckland, 2025, New Zealand

  • Investigative Site

    Hamilton, 3204, New Zealand

  • Investigative Site

    Tauranga, 3110, New Zealand

  • Investigative Site

    Wellington, 6021, New Zealand

  • Investigative Site

    Bucharest, 021105, Romania

  • Investigative Site

    Busan, 49421, South Korea

  • Investigative Site

    Seoul, 03080, South Korea

  • Investigative Site

    Seoul, 05505, South Korea

  • Investigative Site

    Yangsan, 50612, South Korea

  • Investigative Site

    Chiayi City, 60041, Taiwan

  • Investigative Site

    Kaohsiung City, 80756, Taiwan

  • Investigative Site

    Kaohsiung City, 83301, Taiwan

  • Investigative Site

    Taichung, 40705, Taiwan

  • Investigative Site

    Taipei, 100, Taiwan

  • Investigative Site

    Taoyuan City, 33305, Taiwan

  • Investigative Site

    Kyiv, 01135, Ukraine

  • Investigative Site

    Birmingham, B15 2TH, United Kingdom

  • Investigative Site

    London, E11FR, United Kingdom

  • Investigative Site

    London, SE5 9RS, United Kingdom

  • Investigative Site

    Manchester, M8 5RB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.